Developing therapeutic antibodies for cancer treatment, Immune-Onc Therapeutics, Inc. (Immune-Onc) is a clinical-stage cancer immunotherapy company structured around discovery and development of novel myeloid checkpoint inhibitors. Describing themselves as "charting a new course in Immunotherapy", Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitorsManagement's indicated objective is to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that would/will disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints.
